CAPR vs. NTLA, WVE, PHVS, CVAC, CDTX, PAHC, CALT, AUPH, ELVN, and GPCR
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
Capricor Therapeutics vs. Its Competitors
Capricor Therapeutics (NASDAQ:CAPR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Capricor Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.
Capricor Therapeutics has a net margin of -181.71% compared to Intellia Therapeutics' net margin of -1,154.10%. Intellia Therapeutics' return on equity of -56.06% beat Capricor Therapeutics' return on equity.
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Capricor Therapeutics presently has a consensus target price of $22.56, indicating a potential upside of 219.48%. Intellia Therapeutics has a consensus target price of $33.37, indicating a potential upside of 145.36%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Intellia Therapeutics.
Capricor Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Capricor Therapeutics had 14 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for Capricor Therapeutics and 10 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.92 beat Capricor Therapeutics' score of -0.06 indicating that Intellia Therapeutics is being referred to more favorably in the news media.
Summary
Intellia Therapeutics beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 7/25/2025 by MarketBeat.com Staff
Free CAPR Stock Alerts